TABLE 1.

MnB test strains used in clinical trials^a

Company and target population	Trial details (age of participants, no. of participants, ClinicalTrials.gov identifier)	Strain name	Neisseria.org ID	Groupb	Sequence IDc	% Homology to fHBP vaccine antigend	% of responders after dosee:
							2	3
Novartis
Infants	2 mo, 147, NCT00381615	H44/76	1	B, 1	B24, 1.1	100	95	87f
		M01240355	31	A, 3	A47, 3.31	65.4	0	0
		M01240101	15	B, 1	B44, 1.15	85.9	28	47
	6–8 mo, 60, NCT00433914	H44/76-SL	1	B, 1	B24, 1.1	100	100	100g
		M01240101	15	B, 1	B44, 1.15	85.9	67	70
		M01240355	31	A, 3	A47, 3.31	65.4	7	17
	2 mo, 1885, NCT00721396	44/76-SL	1	B, 1	B24, 1.1	100	NDh	99i
Adolescents	11–17 yr, 1631, NCT00661713	44/76	1	B, 1	B24, 1.1	100	99	100j
		1000	25	A, 2	A15, 2.25	68.1	85	86k
		44/76	1	B, 1	B24, 1.1	100	100	100
		95N477	22	A, 2	A10, 2.22	69.3	7	7
Adults	18–40 yr, 70	M01240013	19	A, 2	A22, 2.19	72.4	81	79
		M1390	14	B, 1	B03, 1.14	91.8	96	96
		M3812	12	B, 1	B06, 1.12	93.7	82	79
		M4105	4	B, 1	B16, 1.4	96.1	100	100
		M4458	25	A, 2	A15, 2.25	68.1	79	70
		M6190	6	B, 1	B10, 1.6	94.5	39	43
	18–50 yr, 54, NCT00560313	44/76-SL	1	B, 1	B24, 1.1	100	100	97l
Pfizer
Toddlers	18–36 mo, 99, NCT00387569	PMB1745	45	A, 3	A05, 3.45	100	59	83m
		PMB17	87	B, 1	B02, 1.87	92	38	89
		PMB663	19	A	A22, 2.19	88.9	0	44
		PMB265	13	B, 1	B09, 1.13	88.1	0	11
		PMB3556	1	B, 1	B24, 1.1	86.2	7	20
		PMB1168	45	A, 3	A05, 3.45	100	ND	100
		PMB147	15	B, 1	B44, 1.15	91.6	ND	94
		PMB1256	14	B, 1	B03, 1.14	90.8	ND	82
		PMB1321	19	A	A22, 2.19	88.9	ND	100
Children and adolescents	8–14 yr, 127, NCT00387725	PMB1745	45	A, 3	A05, 3.45	100	86	91n
		PMB663	19	A	A22, 2.19	88.9	53	59
		PMB3556	1	B, 1	B24, 1.1	86.2	29	60
		PMB17	87	B, 1	B02, 1.87	92	69	98
		PMB265	13	B, 1	B09, 1.13	88.1	14	47
Adolescents	11–18 yr, 539, NCT00808028	PMB3302	180	A, 3	A04, 3.180	96.6	97	98o
		PMB1256	14	B, 1	B03, 1.14	90.8	30	68
		PMB2001	187	A, 3	A56, 3.187	98.1	97	96
		PMB2707	15	B, 1	B44, 1.15	91.6	70	87
		PMB1321	19	A, 2	A22, 2.19	88.9	ND	88
		PMB2948	1	B, 1	B24, 1.1	86.2	ND	84
		PMB1745	45	A, 3	A05, 3.45	100	95	97
		PMB17	87	B, 1	B02, 1.87	99	79	90
Young adults	18–25 yr, 103, NCT00297687	PMB1745	45	A, 3	A05, 3.45	100	91	100p
		PMB17	87	B, 1	B02, 1.87	99	82	88
		PMB267	49	A, 2	A17, 2.49	88.1	100	100
		PMB265	13	B, 1	B09, 1.13	88.1	97	96
		PMB663	19	A	A22, 2.19	88.9	64	100
		PMB3556	45	A, 3	A05, 3.45	100	81	100
Adults	18–40 yr, 60, NCT00780806	PMB1745	45	A, 3	A05, 3.45	100	75	94q
		PMB17	87	B, 1	B02, 1.87	99	70	94
		PMB1321	19	A, 2	A22, 2.19	88.9	75	94
		PMB2707	15	B, 1	B44, 1.15	91.6	83	94
		PMB2948	1	B, 1	B24, 1.1	86.2	72	81

^aStrains that express the 4CMenB vaccine homologous PorA or NadA protein are not included in this table, which focuses on SBA responses to fHBP.

^bPfizer subfamily, Novartis variant.

^cPfizer variant number, Novartis subvariant number.

^dB24 (1.1) for Novartis, A05 (3.45) and B01 (1.55) for Pfizer.

^ePercentage of responders at 1 month after the indicated dose.

^fPercentage of participants with hSBA titers of ≥4 (77).

^gND, not determined.

^hPercentage of participants with hSBA titers of ≥1:4 (83).

ⁱPercentage of participants with hSBA titers of ≥1:5 (78).

^jPercentage of participants with hSBA titers of ≥4 (82).

^kPercentage of participants with hSBA titers of ≥4 (127).

^lPercentage of participants with hSBA titers of ≥4 (79).

^mPercentage of participants with ≥4-fold rise in hSBA titer (128).

ⁿPercentage of participants with hSBA titers of ≥1:4 (129).

^oPercentage of participants with hSBA titers equal to or greater than the limit of quantitation (LOQ) (80).

^pPercentage of participants with hSBA titers of ≥1:4 (81).

^qPercentage of participants with hSBA titers of ≥1:4 (130).